ACADIA Pharmaceuticals

ACADNASDAQ

CNS-focused small-molecule development and commercialization platform

Drafted with AI assistance from public sources and not individually reviewed by an editor; last updated 2026-04-09. Published by Blane Jackson, DDS, MBA. Educational analysis only. Read the editorial policy and disclosures.

text updated 2026-04-09, 177 days ago · archived: kept for reference, not maintained · where each field comes from

central nervous system rare disease

Key figures from SEC filings

We have not parsed a 10-Q or 10-K for ACAD yet, so this page shows no cash, burn or runway figure rather than an estimate. Revenue stage: Commercial.

Upcoming catalysts

ADVANCE-2 master protocol: ACP-204 in Alzheimer's disease psychosis — primary completion

2028-01

Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov

Trial milestoneSignificant

ACP-211 MDD: ACP-211 in Major depressive disorder with inadequate response — primary completion

2027-08

Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov

Trial milestoneModerate

Pipeline

Drug	Indication	Phase	Expected data
Nuplazid	Parkinson disease psychosis	Approved	Not disclosed	▼
Daybue	Rett syndrome	Approved	Not disclosed	▼
ACP-204	Alzheimer disease psychosis	Phase 2	Not disclosed	▼

Analysis

We have not yet written an analysis of ACADIA Pharmaceuticals that is specific and current enough to publish. Earlier text here was removed rather than left up: on most profiles it was a template shared with other companies, and where a correction is listed above, it was written before the facts changed. The filing figures, pipeline and sourced catalysts on this page are current; the written thesis will be added from them.

Trade ACAD commission-free on Webullvia Webull · Affiliate

Comparable companies

BiogenNeurocrine BiosciencesSupernus Pharmaceuticals

Sponsor's late-stage trial record

ACADIA Pharmaceuticals has 38 Phase 2 or 3 studies on ClinicalTrials.gov: 23 completed, 9 stopped early, 6 ongoing.

Completed

Stopped early

Ongoing

Stopped early

NCT06420297Phase 3 · started 2024 · terminated
Carbetocin in hyperphagia in prader-willi syndrome · n=168
Reason given: Primary efficacy endpoint was not met in the parent study (ACP-101-302). Based on review of available data, continued administration of investigational product in ACP-101-303 was not considered likely to provide significant clinical benefit.
NCT05555615Phase 2/3 · started 2022 · terminated
Pimavanserin in irritability associated with autism spectrum disorder · n=209
Reason given: The study was terminated for business reasons and not due to safety concerns.
DAFFODIL™Phase 2/3 · started 2021 · terminated
Trofinetide in rett syndrome · n=15
Reason given: As a result of marketing approval of trofinetide on 10 March 2023, the study was terminated by the Sponsor with the intent of switching patients to commercially available product.
NCT05008835Phase 2 · started 2021 · terminated
ACP-044 Dose A in osteoarthritis pain · n=61
Reason given: Study was terminated for business reasons.
NCT04776746Phase 3 · started 2020 · terminated
trofinetide in rett syndrome · n=77
Reason given: As a result of marketing approval of trofinetide on 10 March 2023, the study was terminated by the Sponsor with the intent of switching patients to commercially available product.
NCT04164758Phase 2 · started 2019 · terminated
Pimavanserin in parkinson's disease · n=11
Reason given: Study enrollment impacted by COVID-19 pandemic and Sponsor terminated for business reasons
NCT04000009Phase 3 · started 2019 · terminated
Pimavanserin in adjunctive treatment of major depressive disorder · n=235
Reason given: The study was terminated for business reasons and not due to safety concerns.
NCT03121586Phase 3 · started 2017 · terminated
Pimavanserin in schizophrenia · n=995
No reason recorded in the registry.
NCT02992132Phase 2 · started 2016 · terminated
Pimavanserin 34 mg in agitation and aggression in alzheimer's disease · n=111
No reason recorded in the registry.

Counts cover interventional Phase 2 and Phase 3 studies registered under this sponsor name, retrieved 2026-09-28 from ClinicalTrials.gov API v2. Trials stop for many reasons — futility, safety, enrollment, funding, or a decision to back a different programme — and the registry often does not say which. This is the sponsor's record, not a prediction about any specific readout.